Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Incyte Corporation before investing.

In this article, we go over a few key elements for understanding Incyte Corporation’s stock price such as:

• Incyte Corporation’s current stock price and volume
• Why Incyte Corporation’s stock price changed recently
• Upgrades and downgrades for INCY from analysts
• INCY’s stock price momentum as measured by its relative strength

About Incyte Corporation (INCY)

Before we jump into Incyte Corporation’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company’s clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Want to learn more about Incyte Corporation’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Incyte Corporation.

Incyte Corporation’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Incyte Corporation’s stock price was $119.520.

Incyte Corporation is down 2.82% from its previous closing price of $122.990.

During the last market session, Incyte Corporation’s stock traded between $118.440 and $122.750. Currently, there are approximately 200.38 million shares outstanding for Incyte Corporation.

Incyte Corporation’s price-earnings (P/E) ratio is currently at 15.2, which is low compared to the Biotechnology industry median of 19. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Incyte Corporation Stock Price History

Incyte Corporation’s (INCY) price is currently up 5.43% so far this month.

During the month of July, Incyte Corporation’s stock price has reached a high of $132.600 and a low of $110.560.

Over the last year, Incyte Corporation has hit prices as high as $132.600 and as low as $73.805. Year to date, Incyte Corporation’s stock is up 21.01%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Incyte Corporation Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded Incyte Corporation’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Incyte Corporation’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Incyte Corporation’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Incyte Corporation’s current valuation based on AAII’s Value Grade is a C, which means it is considered to be Average.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Incyte Corporation (INCY) by visiting AAII Stock Evaluator.

Relative Price Strength of Incyte Corporation

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Incyte Corporation has a weighted four-quarter relative price strength of 10.39%, which translates to a Momentum Score of 83 and is considered to be Very Strong.

Want to learn more about how Incyte Corporation is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Incyte Corporation Stock Price: Bottom Line

As of July 31, 2026, Incyte Corporation’s stock price is $119.520, which is down 2.82% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Incyte Corporation stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.